Literature DB >> 9850171

Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up.

H D Hoerl1, W R Hart.   

Abstract

Prognostic data for ovarian mucinous carcinoma are limited and difficult to interpret because of differing diagnostic criteria and inclusion of secondary tumors. To better characterize these neoplasms, 49 primary ovarian mucinous tumors diagnosed as carcinoma by the Hart and Norris criteria and staged by the FIGO system were studied. Forty-four tumors (90%) were stage I, four were stage III and one was unstaged. Sixteen tumors (33%) were classified as intraglandular ("noninvasive") carcinoma; all were stage I and all patients were alive without tumor after 4-216 months (mean, 74 months); two patients had received adjuvant chemotherapy. Stromal invasion was present in the remaining 33 cases (67%), including 19 tumors with extensive invasion and 14 with one or more discrete foci of microinvasion (each focus < or = 1 mm). The microinvasive tumors were reclassified into intraglandular carcinoma with microinvasion (nine cases) and borderline (low malignant potential) tumor with microinvasion (five cases). All microinvasive tumors were stage I and none recurred after postoperative intervals of 9-176 months (mean, 71 months) for the microinvasive carcinomas and 33-117 months (mean, 60 months) for the microinvasive borderline tumors; only 1 of the 14 patients received adjuvant chemotherapy. All 19 extensively invasive carcinomas also had intraglandular carcinoma. Fourteen were stage I, four were stage III, and one was unstaged. Eleven (79%) of the stage I patients were alive without tumor after 10-220 months (mean, 110 months), including six who received chemotherapy; one was dead without tumor and two developed progressive disease (one had received adjuvant chemotherapy). The four extensively invasive stage III carcinomas were fatal after 1-59 months. The unstaged patient received adjuvant chemotherapy and was alive without recurrence at 98 months. Conclusions of this study are as follows: (1) primary mucinous carcinomas are very uncommon tumors, after rigorous exclusion of metastatic carcinomas and tumors associated with pseudomyxoma peritonei; (2) bilaterality is not a feature of primary mucinous carcinomas; (3) FIGO stage is the single most important prognostic factor, with stage I carcinomas having a very favorable prognosis; (4) stage I carcinomas that metastasize have extensive stromal invasion; (5) extensive stromal invasion is found only in tumors with a component of intraglandular carcinoma; (6) high-stage carcinomas invariably contain extensively invasive carcinoma and have a very poor prognosis; and (7) stromal microinvasion with individual foci not exceeding 1 mm does not appear to be an adverse factor in either carcinomas or borderline tumors of stage I.

Entities:  

Mesh:

Year:  1998        PMID: 9850171     DOI: 10.1097/00000478-199812000-00002

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; Mark F Brady; Subodh M Lele; Helen Michael; Benjamin Greer; Michael A Bookman
Journal:  Cancer       Date:  2010-09-22       Impact factor: 6.860

Review 2.  [Histological grading of epithelial ovarian cancer. Review and recommendation].

Authors:  S Hauptmann; A du Bois; I Meinhold-Herlein; J Pfisterer; S Avril
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

3.  HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.

Authors:  Sang Kyum Kim; Nam Hoon Cho
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 4.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.

Authors:  Jaime Prat
Journal:  Virchows Arch       Date:  2012-02-10       Impact factor: 4.064

5.  Mucinous borderline ovarian tumors: pathological and prognostic study at Salah Azaiez Institute.

Authors:  Ghada Sahraoui; Asma Fitouri; Lamia Charfi; Maha Driss; Maher Slimane; Monia Hechiche; Karima Mrad; Raoudha Doghri
Journal:  Pan Afr Med J       Date:  2022-04-29

6.  Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis.

Authors:  Sang Kyum Kim; Si Young Song; Sunghoon Kim; Nam Hoon Cho; Ga Won Yim; Sang Wun Kim; Young Tae Kim; Eun Ji Nam
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

Review 7.  Recent concepts of ovarian carcinogenesis: type I and type II.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Ikuo Konishi
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

Review 8.  Pathobiology of ovarian carcinomas.

Authors:  Mojgan Devouassoux-Shisheboran; Catherine Genestie
Journal:  Chin J Cancer       Date:  2015-01

Review 9.  Ovarian cancer: pathology, biology, and disease models.

Authors:  Daniel G Rosen; Gong Yang; Guangzhi Liu; Imelda Mercado-Uribe; Bin Chang; Xue Sherry Xiao; Jingfang Zheng; Feng-Xia Xue; Jinsong Liu
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

10.  Proposal for Creating a Guideline for Cancer Registration of Microinvasive Tumors of the Breast and Ovary (II).

Authors:  Jin Hee Sohn; Gyungyub Gong; Kyu Rae Kim; Chang Suk Kang; Youn Soo Lee; Jin Man Kim; Woo Hee Jung; Kwang Sun Suh
Journal:  Korean J Pathol       Date:  2012-06-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.